Executive Management

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Brad McConn serves as the Chief Financial Officer for ImmunoPrecise Antibodies. He is responsible for oversight of the company’s financial reporting, financial planning & analysis, and complex accounting research. Prior to his current role he served as the Director of Financial Planning & Analysis for ImmunoPrecise Antibodies, and previously worked as an analyst in the real estate industry, focusing on a broad range of financial processes and business development. He is a CFA® charterholder, and holds a Bachelor of Arts in Mathematics with Minors in Chemistry and Business.

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Kari Graber serves as the Vice President of Commercial Services for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Dr. Barry Duplantis serves as Vice President of Client Relations for ImmunoPrecise Antibodies and is responsible for managing and coordinating all sales- related activities. He is a scientific entrepreneur and business development specialist with over 10 years experience in the commercial application of drug and vaccine discovery platforms. Prior to his appoint to VP of Client Relations he served as the Director of Client Relations for ImmunoPrecise Antibodies (Canada) and was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Ingrid Brands cofounded and became CEO of Biostrand in 2019, with a commitment to establishing it as a global player in the genetic research space. Dr. Brands is an entrepreneur and seasoned leader with more than two decades of senior research and management experience. In her 25-year career in medicine and neurorehabilitation she has contributed to innovative approaches in neuropsychological rehabilitation and enhanced the care of patients suffering from acquired brain injuries.

Dr. Brands has held senior research posts at Libra Revalidatie & Audiologie, Eindhoven, and the department of Rehabilitation of Erasmus University, the Netherlands. She was sub-director of education in Physical Medicine and Rehabilitation (PM&R) at Libra and active in several committees of the Dutch association of PM&R. Dr. Brands has a PhD in neurorehabilitation, University of Maastricht, The Netherlands and graduated Magna cum Laude in Medicine, University of Leuven, Belgium. Specializing in PM&R.

Dr. Roland Romijn is the Head of General Operations of the Utrecht site of IPA (Europe). Roland is co-founder of U-Protein Express BV, which became part of ImmunoPrecise in 2017. He works closely with the executive team and all IPA sites to streamline and optimize large scale recombinant protein production, via the rPEx® platform. He is also responsible for coordinating catalog product sales and the introduction of new products.

Dr. Romijn completed his PhD at the Department of Hematology of the University Medical Center Utrecht, and the Department of Crystal and Structural Chemistry of Utrecht University, on the structure and function of von Willebrand Factor.